Abstract
The mechanisms by which patients infected with T. cruzi develop or not the disease are not completely understood. We investigated the importance of parasite persistence as a factor in generating cardiomyopathy. Fifty trypomastigote forms from the Tulahuen strain were used as inoculum for 160 Albino Swiss mice. Parasitemia, survival, histopathological and electrocardiographic studies were done on days 90, 180, 270 and 360 post infection (pi). Parasite presence in the tissues was determined by immunofluorescence. Maximum parasitemia was observed on day 21pi and became negative on day 42pi. By day 90pi, 50% of the infected mice presented electrocardiographic alterations and 67% by day 360pi; the non infected group of mice didn’t present elecrocardiographic alterations. Inflammatory infiltrates were observed throughout the infection, with a higher percentage in those mice with electrocardiographic alterations. The presence of the parasite was observed throughout the infection in skeletal muscle samples and on day 90pi in the myocardium. The highest mortality occurred on day 21pi, surviving 10% of the mice until the end of the experiments. These results demonstrate the presence of the parasite in the host tissues along the infection which could produce the injuries found in the myocardium and the electrocardiographic alterations.
Keywords: Trypanosoma cruzi, chagasic cardiomyopathy, persistence
Anti-Infective Agents
Title:Persistence of Trypanosoma cruzi in Experimental Chagasic Cardiomyopathy
Volume: 10 Issue: 2
Author(s): Bazan Carolina, Micucci Lorena, Fauro Romina, Triquel M. Fernanda, Lo Presti M. Silvina, Baez Alejandra, Strauss Mariana, Camino Gaston, Paglini-Oliva Patricia and Rivarola H. Walter
Affiliation:
Keywords: Trypanosoma cruzi, chagasic cardiomyopathy, persistence
Abstract: The mechanisms by which patients infected with T. cruzi develop or not the disease are not completely understood. We investigated the importance of parasite persistence as a factor in generating cardiomyopathy. Fifty trypomastigote forms from the Tulahuen strain were used as inoculum for 160 Albino Swiss mice. Parasitemia, survival, histopathological and electrocardiographic studies were done on days 90, 180, 270 and 360 post infection (pi). Parasite presence in the tissues was determined by immunofluorescence. Maximum parasitemia was observed on day 21pi and became negative on day 42pi. By day 90pi, 50% of the infected mice presented electrocardiographic alterations and 67% by day 360pi; the non infected group of mice didn’t present elecrocardiographic alterations. Inflammatory infiltrates were observed throughout the infection, with a higher percentage in those mice with electrocardiographic alterations. The presence of the parasite was observed throughout the infection in skeletal muscle samples and on day 90pi in the myocardium. The highest mortality occurred on day 21pi, surviving 10% of the mice until the end of the experiments. These results demonstrate the presence of the parasite in the host tissues along the infection which could produce the injuries found in the myocardium and the electrocardiographic alterations.
Export Options
About this article
Cite this article as:
Carolina Bazan, Lorena Micucci, Romina Fauro, M. Fernanda Triquel, Presti M. Silvina Lo, Alejandra Baez, Mariana Strauss, Gaston Camino, Patricia Paglini-Oliva and H. Walter Rivarola, Persistence of Trypanosoma cruzi in Experimental Chagasic Cardiomyopathy, Anti-Infective Agents 2012; 10 (2) . https://dx.doi.org/10.2174/2211362611208020136
DOI https://dx.doi.org/10.2174/2211362611208020136 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Subject Index to Volume 4
Current Gene Therapy New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Essential Roles of Toll-Like Receptors in Atherosclerosis
Current Medicinal Chemistry Pathogenesis and Clinical Features of Obesity and Insulin Resistance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Genomic and Non-genomic Effects of Aldosterone
Current Signal Transduction Therapy The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention
Current Protein & Peptide Science Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Hypocholesterolemia
Current Vascular Pharmacology The Role of Obesity in Cardiomyopathy and Nephropathy
Current Pharmaceutical Design Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Late Sodium Current Inhibition: The Most Promising Antiarrhythmic Principle in the Near Future?
Current Medicinal Chemistry MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Impact of Matrix Metalloproteinases on Atherosclerosis
Current Drug Targets Identification of Important Positions within miRNAs by Integrating Sequential and Structural Features
Current Protein & Peptide Science Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design Drug Repositioning: A Smart Approach for Combating SARS-CoV-2
Anti-Infective Agents